Gefitinib (ZD1839)

目录号：S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1574.78	现货
100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献95篇：

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )
Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )
Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )
Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )
Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )
PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )
Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

客户使用该产品的14个实验数据：

c, HCC4006 lung cancer cells that have acquired a high-mesenchymal state concomitant with becoming resistant to gefitinib (red curve) exhibit increased sensitivity to GPX4 inhibition.

Nature, 2017, 547(7664):453-457. Gefitinib (ZD1839) purchased from Selleck.

Perturbation of EGFR by its ligand EGF and gefitinib (ZD-1839 Iressat; inhibits EGFR) produces opposite responses in the predicted EGFR target genes SOCS2 and NR2E1.

Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck.
Effects of shRNA-mediated RECK depletion on EGFR signaling in MEFs. (a) Immunoblotting (IB) of the indicated proteins in wild-type MEFs transduced with the indicated shRNAs and cultured for 48 h in the presence of 0.1% dimethyl sulfoxide (DMSO; vehicle) or 1 mM gefitinib (S1025, Selleck Chemicals,Houston, TX, USA). (b) Immunoprecipitation from whole lysates of cells from panel a with an anti-phosphorylated tyrosine (pTyr) antibody. Precipitates from 500 mg protein in whole cell lysates (upper) or 20 mg protein in whole cell lysates (lower) were analyzed by IB with anti-EGFR antibody.

Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck.

(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 lM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck.
LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck.

Suppression of EGFR signaling by Gefitinib is dose dependent and non- toxic at millimolar concentrations.Results from plaque reduction tests of Hep2 cells infected with VACV(12.5pfu/well) treated with a serial dilution of Gefitinib (1000-0.01 m) and analyzed for (A)proliferation as indicator of cytotoxicity,(B) IC50 of plaque size inhibition, (C)dose dependent inhibition of EGFR-ERK1/2signaling and VACV proteins by Western blot analysis (pEGFR detection was obtained from a different experiment with identicals ettings) and (D)dose dependent inhibition of orthopoxvirus genome replication by real-time PCR.Untreated VACV infectedcells and uninfected cells are shown as controls in the right panel.

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.
A circular zone of EGFR activated but uninfected cells facilitate virus induced plaque development , efficiently blocked by Gefitinib. (A)Immun of luorescent staining of aplaque reduction tests with Hep2 cells 24,48,72 and 96 h after VACV infection (6.25pfu/chamber). VACV infected cells(green) were visualized by human IgG directed to orthopoxviruses (VIG) detected with a secondary FITC labelled antibody. Uninfected cells with activated EGFR signaling(red) are detected with a secondary Cy3labelled antibody. Positive cells for both , VACV and phosphorylated EGFR are shown in yellow(merge). Cellular nuclei are counterstained with DAPI. (B)Immunofluorescent staining of a plaque reduction test as described for (A) and treated with three different Gefitinib concentrations (1000 nM, 1 nM, and 0.01 nM) . The test was analyzed 96h afterVACV infection.Uninfected cells are shown as controls. Magnification100×.(For interpretation of the references to color in this figure legend , the reader is referred to the web version of the article.)

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.

Susceptibility of lung cancer cells to cytolytic activity of NK-92 cells after treatment with EGFR inhibitors. Three lung cancer cells were untreated (open circle) or treated with 10 μM erlotinib or gefitinib (black filled square or black filled triangle) for 24 hours. The lung cancer cells were cocultured with NK-92 cells at indicated effector to target ratio (E:T ratio). To determine the specificity of NKG2D-mediated cytolysis of lung cancer cells, NK-92 cells were preincubated with blocking mAb against NKG2D before the assay (gray filled square and triangle) and correspond-ing isotype mAb (open square and triangle).

J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck.
Inhibition of 5-HT-induced 5-HT3A and 5-HT3AB receptor currents.

Eur J Pharmacol, 2017, 821:21-28. Gefitinib (ZD1839) purchased from Selleck.

The EGF-dependent increased association of PCM1 and AZI1 requires EGFR kinase activity. ZD1839 (Iressa)—EGFR tyrosine kinase inhibitor.

Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck.
Reduction of GPER expression in HCC1806 cells after treatment with gefitinib. (A) Concentration dependence. HCC1806 cells were treated with 50-500 nM gefitinib for 48 h. GPER was detected by western blotting. (B) Time dependence. HCC1806 cells were treated with 200 nM gefitinib for 24-96 h. ^ap<0.05 vs. control; ^bp<0.001 vs. control. Mean values and SE of three independent experiments are shown. (C) Representative western blotting of concentration dependence. (D) Representative western blotting of time dependence

Oncol Rep, 2017, 37(2):1212-1218. Gefitinib (ZD1839) purchased from Selleck.

Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck.
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Gefitinib for 24 hours.

2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck.

MTT assay result. 0-500nM Gefitinib treated with H1299, H358, H25 and HCC827 cell lines by 72h, Proliferation rate was tested.

2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck.

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHYeJZzUUN3ME2wMlA2PCEQvF2=	MoPjNVY2OTZ2N{O=
NIH3T3	NInCTolHfW6ldHnvckBCe3OjeR?=	NID1UI8xNjJizszN	NWP4WJQ3OiCq	MnzVSG1UVw>?	MXvJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	NUD2Om95OTZ2OECyPFQ>
COS7	M2P1c2Z2dmO2aX;uJGF{e2G7	M{jIV\|k3KM7:TR?=			NEPwWJdKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	NHfyc28yPzF5OEeyNi=>
A549	MnrWR5l1d3SxeHnjJGF{e2G7		MX[5OkBp	M1zP[2ROW09?	NGjZXIRKSzVyPUGzMlU6KM7:TR?=	NX;KPHpvOTh\|MUO4NFc>
K562	NU[4SZlLS3m2b4TvfIlkKEG\|c3H5		MXW5OkBp	MnfiSG1UVw>?	MnXOTWM2OD17LkO2JO69VQ>?	NFTGNXAyQDNzM{iwOy=>
MDA-MB-231	M{PWNmN6fG:2b4jpZ{BCe3OjeR?=		MoL5PVYhcA>?	NVj4fXZ{TE2VTx?=	NXSwWnpXUUN3ME2zOk43OSEQvF2=	NXyyS\|ZvOTh\|MUO4NFc>
MOLT4	NWfQTnd5S3m2b4TvfIlkKEG\|c3H5		M4[4Ulk3KGh?	NXu0OoRsTE2VTx?=	NXvBWlZ{UUN3ME2xOU4xOiEQvF2=	M{PCfFE5OzF\|OEC3
MCF7	MVTDfZRwfG:6aXOgRZN{[Xl?	MnvjOVAh\|ryP	M{\Pd\|czKGh?		Mny5TWM2OD1zMj6wOUDPxE1?	NVPCSFR6OTh5N{G4NVk>
BT474	NH:0foVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIG0OlQ4OiCq		NEDkPG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXSRoIzKHerdHigSWM2OCCxZjCwMlMh\|ryP	NVz2ZVNQOTlyMki0NlQ>
HN5	M1zKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1rH[FczKGh?		MojjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTkWgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEWFNUCgc4YhOC5yMTFOwG0>	M333S\|E6ODJ6NEK0
BA/F3	NYnmSoljS3m2b4TvfIlkKEG\|c3H5		NXHhcWVIPzJiaB?=		NU\3N\|NkS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?	MoSzNVkzOzl{Mkm=
NIH3T3	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrJelE4OiCq		NETzNYJIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBPUUhxM2SzJINmdGy\|IHX4dJJme3Orbneg[ZJDOiCpZX7lJJdqfGhiSVO1NEBw\iByLkW0JO69VQ>?	MmrvNVk3PjV\|N{e=
MCF7 MX	MUjGeY5kfGmxbjDBd5NigQ>?		MnzvN\|AhdWmw		NVj5XZozUW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4yKM7:TR?=	NHTxVIgyQTl\|Mkm2NC=>
A431	NIewZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TzV\|ExKM7:TR?=	MnyxO\|IhcA>?		MlfoS2k2OD1yLkWxOEDPxE1?	MWSxPVk3QTR4NR?=
A431	Mn6yT4lv[XOnIFHzd4F6	M1e2TlAvOSEQvF2=	NFPXT4EyKGh?		Mn7pTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	M4LrXFE6QTZ7NE[1
A431	Mlv1T4lv[XOnIFHzd4F6	NEHQ[JoyODBizszN	M4XhO\|ExKG2rbh?=		MYTQdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	MYexPVk3QTR4NR?=
Sf9	M2\zTmtqdmG\|ZTDBd5NigQ>?		NWTSVJlpOTBibXnu	NV7lVFB1TE2VTx?=	MlvtTY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJJm[2WydH;yJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM{KM7:TR?=	MlrDNlAxPTZ2MkW=
NCI-H1975	NHfv[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXS1JO69VQ>?	MVO3NkBp		NXz6WlNPUUN3ME24MlI3KM7:TR?=	NEfKWmgzODF3MU[3NC=>
NCI-H1975	NWnLc\|FVU2mwYYPlJGF{e2G7	M1TQTVExKM7:TR?=			NUj6PHlKUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NXfGOmlbOjBzNUG2O\|A>
NCI-H1975	NFn3fGNHfW6ldHnvckBCe3OjeR?=	Ml3tNVAh\|ryP			NY\xUGxWUW6qaXLpeIlwdiCxZjDFVmJDOiCjdYTvdIhwe3Cqb4L5cIF1cW:w	M4\YWlIxOTVzNkew
NCI-H1975	NFqxc4pHfW6ldHnvckBCe3OjeR?=	Mlf0OUDPxE1?	M1LK[FQ5KGh?		NX3SNHN{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2VvMx?=	MXOyNFE2OTZ5MB?=
A375	NHjMNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV31RXRFPDhiaB?=		MWXJR\|UxRTJyLkW1JO69VQ>?	NF;qVlczODNyNEWzOy=>
SMMC7721	NX70SnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUH4e2NxPDhiaB?=		NUXVdWhPUUN3ME2zN{4yOiEQvF2=	NEC5OHozODNyNEWzOy=>
DU145	NHHL[mZEgXSxdH;4bYMhSXO\|YYm=		MnTNOUBl	NE\D[GdFVVOR	NECzeppKSzVyPUSyMlE4KM7:TR?=	M{nIOlIxPDZ4NUW1
MIAPaCa2	MoL4R5l1d3SxeHnjJGF{e2G7		NYHWb\|ZtPSCm	NWjsZY93TE2VTx?=	MlzhTWM2OD13MD62NkDPxE1?	NILTRlAzODR4NkW1OS=>
PANC1	MoDkR5l1d3SxeHnjJGF{e2G7		NHnqUIw2KGR?	NUPpS2s3TE2VTx?=	NYroO3NkUUN3ME20NE41OiEQvF2=	NV65Wo1DOjB2Nk[1OVU>
PC9	NH\UTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LHcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	MUmyNVIxQDhyMh?=
PC9	NEPHblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDndo94fGhvcnXzbZN1[W62IHj1cYFvKFCFOTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTTd2Nm;BO\|UxN1R5OUDNJI12fGGwdDD3bZRpKEWFNUCgc4YhPyEQvF2=	M1LRfFIyOjB6OECy
PC3	M{LNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xNEDPxE1?	M4rwfVczKGh?	MnHqSG1UVw>?	M125RWlEPTB;Nz60JO69VQ>?	MkT4NlE{PTN3NE[=
MDA-MB-468	NXrKW\|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7BeGUyODBizszN	M2CxUFQ5KGh?	NVHM[XJNTE2VTx?=	MnjlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdIm=	MWiyNVQzQTZ\|Mh?=
Plasmodium falciparum					NIjLcpFyUFSVIIDyc4ZqdGmwZzDmc5IhcW6qaXLpeI9zeyCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbh?=	MWqyNVgyPzB2NR?=
NCI-H1993	NG\MfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvaWpl1PzJiaB?=	MojNSG1UVw>?	NFzFWZlKSzVyPUCuNUDPxE1?	M3v0dlIyQTF4NEOz
NCI-H292	NHHVN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1Oyd\|czKGh?	NUPWUnJNTE2VTx?=	NWTjXpdpUUN3ME2wMlAzKM7:TR?=	NYX3OXpbOjF7MU[0N\|M>
A431	MlS2T4lv[XOnIFHzd4F6		NInwbVAzKGh?	NGDC[G9FVVOR	NXu0Sm5PUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKHerdHigTWM2OCCxZjCwMlAxOSEQvF2=	MmHWNlIyODFzM{K=
MCF7	NF\YcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fWU\|ExOMLizsznM41N	MVG0PEBp	M1HmSGROW09?	M3LKc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJIdmdmVid3n0bEBKSzVyIH;mJFEzNjB3IN88US=>	NIjWTnUzOjFzOUGzNC=>
BT474	MUDDfZRwfG:6aXOgRZN{[Xl?	MkHVNVAh\|ryP	MX:0PEBp		MWTDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	MVeyNlE{QDNyOB?=
MCF7	MnqwR5l1d3SxeHnjJGF{e2G7	MmTVNVAh\|ryP	NFvaU4c1QCCq		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy\|	NWP3ToIxOjJzM{izNFg>
HCC827	NWnxNWJKU2mwYYPlJGF{e2G7	NWPxSW03OC5zMkWg{txO	NYC4V3BIOjRiaB?=	Mk\oSG1UVw>?	NFi2T2FKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MV2yNlM{QTN2Mh?=
HCC827	MVXLbY5ie2ViQYPzZZk>	MnzWNE4yOjVizszN	NHTvO5UzPCCq	M4P3b2ROW09?	NXvBSGtrUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	MnP4NlI{Ozl\|NEK=
HCC827	MmS2T4lv[XOnIFHzd4F6	MYKwMlEzPSEQvF2=	M1H1SlI1KGh?	Moe1SG1UVw>?	MoPlTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	M37CeVIzOzN7M{Sy
A431	NHLWU4pMcW6jc3WgRZN{[Xl?	NVHHOGprOTByIN88US=>	MWWzNEBucW5?		NGO4UHZKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MnnaNlI3QTh5OEK=
H460	Mk\FR5l1d3SxeHnjJGF{e2G7		M4fhW\|czKGh?		MnfhTWM2OD13LkW5JO69VQ>?	MX6yNlczPzR2OR?=
HT-29	MVHDfZRwfG:6aXOgRZN{[Xl?		NILCRlM4OiCq		NF7vcpdKSzVyPUOuN\|Yh\|ryP	M4jxbFIzPzJ5NES5
SGC7901	NEHx[ZZEgXSxdH;4bYMhSXO\|YYm=		NVr1S4FFPzJiaB?=		M4XOUWlEPTB;MUCuNlYh\|ryP	Mk\ZNlI4Ojd2NEm=
A498	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7uUXZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUWkNid3n0bEBKSzVyIH;mJFgvPiEQvF2=	NGD4eIQzOjhzOEi0PC=>
Calu3	NG\1[VZEgXSxdH;4bYMhSXO\|YYm=	MkLGNVAh\|rypL33M	NGe1bok4OiCq		NUG3ZWsyUUN3ME2xMlYh\|ryP	MXKyN\|EyPjF4OB?=
FADU	NYfae4psS3m2b4TvfIlkKEG\|c3H5	MUixNEDPxGdxbVy=	NXzXWXNZPzJiaB?=		NXWycXZYUUN3ME2wMlA2KM7:TR?=	NYHjXVBuOjNzMU[xOlg>
HCC827	NXP5RYxyS3m2b4TvfIlkKEG\|c3H5	NFTRV3gyOCEQvHevcWw>	MXS3NkBp		M2\MemlEPTB;MD6wNFE2KM7:TR?=	NEnUTnYzOzFzNkG2PC=>
PC9	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESxe2IyOCEQvHevcWw>	NHfuVJU4OiCq		M1ftZmlEPTB;MD6wNFE1KM7:TR?=	M{XRelI{OTF4MU[4
Sf9	NHvxNnpMcW6jc3WgRZN{[Xl?		M2XNN\|EhcA>?	M3jiVWROW09?	NHrCUWdKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	NVTpblR4OjN4MUG2PVE>
16HBE14o-	MnKzR5l1d3SxeHnjJGF{e2G7	M{DHPFExKM7:TR?=	MYO3NkBp	NFTQOGxFVVOR	NX3lZWpwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOT[KQlWxOI8uKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhTUeIUjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMUKuO\|Eh\|ryP	MYiyN\|Y3QDR2MR?=
NCI-H1975	MnW4R5l1d3SxeHnjJGF{e2G7	NInr[WEyOCEQvF2=	MmqyO\|IhcA>?	MXnEUXNQ	NYHte\|d{S3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch\|ryP	NY\m[2diOjN4Nki0OFE>
16HBE	NW[2[3J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXTjOmVKPzJiaB?=	MWfEUXNQ	M2\mdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMU\IRmUh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTUeIUjD3bZRpKEmFNUCgc4YhOS54MEGg{txO	NV33ZndzOjN5OUKzNVg>
16HBE	MYrGeY5kfGmxbjDBd5NigQ>?	M3nweFExOCEQvF2=	M2m2bVE2OCCvaX6=	Mn;USG1UVw>?	NHjDRmpKdmS3Y4Tpc44hd2Zibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44hcW5iaIXtZY4hOT[KQlWgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgSWdHWg>?	Ml;ZNlM4QTJ\|MUi=
A549	NI\kfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF\r[XQ4OiCq	MmTESG1UVw>?	M{fScWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGVITlJxaz3SZZMh\GWyZX7k[Y51KGi3bXHuJGE2PDliY3XscJMhf2m2aDDJR\|UxKG:oIESuOlI3KM7:TR?=	MVWyN\|c6OjNzOB?=
SH-SY5Y	MlfPR5l1d3SxeHnjJGF{e2G7		NXG2SJRlPzJiaB?=		NGS4VYhKSzVyPUG4MlIyKM7:TR?=	NGjSPJgzOzh5MUmwPS=>
LoVo	MkPKT4lv[XOnIFHzd4F6		NVS4e3lkOiBiaB?=	Ml3ZSG1UVw>?	NYHydYtIUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh\|ryP	MoPQNlM6OzB7OUS=
PC9	NVLFdYljU2mwYYPlJGF{e2G7		M1zudFIhcA>?	M{TBWGROW09?	NUf4cnBnUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NFPRfpkzOzl\|MEm5OC=>
HCC827	NGDiNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MljmO\|IhcA>?		NXXhNGhXUUN3ME2wMlAyOiEQvF2=	Mlj2NlM6PzNzNki=
A549	M2\TWWtqdmG\|ZTDBd5NigQ>?	MmnhNUDPxE1?	MoPrNUBp	M1XPR2ROW09?	MWnJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN\|k6KM7:TR?=	Mk\yNlM6QDh\|NUS=
A549	MonWSpVv[3Srb36gRZN{[Xl?	MV6xJO69VQ>?	MVuxJIg>	M2fDV2ROW09?	NHvBZVhE\WyudXzhdkB2eHSja3W=	M1zjdFI{QTh6M{W0
HCC827	MmH0T4lv[XOnIFHzd4F6	NWXLdVUyOC53IN88US=>	NWfwNodtOiCq	NH21c45FVVOR	NGTMVGlKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	MViyN\|k6OzN{OB?=
HCC827	NHryNXFHfW6ldHnvckBCe3OjeR?=	MWKwMlUh\|ryP	MkPTNkBp	MXnEUXNQ	NYCwW\|hUUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	MYOyN\|k6OzN{OB?=
HCC827	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPwSXIyOCEQvF2=	M2PVTVczKGh?	M4TxZmROW09?	NGrGRoVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1{\W6\|aYTpeoUhcHWvYX6gTGNEQDJ5IHPlcIx{KGijcnLvdolv\yCHR1\SJGU4PDZidH:gRVc2OCCmZXzleIlwdiC5aYToJGlEPTBib3[gNE4xODV6MTFOwG0>	MYGyOFA2OzZ5NB?=
A431	M17PZmtqdmG\|ZTDBd5NigQ>?	M{fNT\|ExOCEQvF2=	NULNTY1pOzBibXnu		MUDJcohq[mm2aX;uJI9nKEWJRmKgbY4he2inZDDt[Y1jemGwZTD2[ZNq[2ynczD3bZRpKEmFNUCgc4YhOS5zIN88US=>	M1HEV\|I1ODl2NEOy
BCRP-MDCK2	M3XxbmZ2dmO2aX;uJGF{e2G7	NGHrS3cyNjhizszN	NYexPJo4PzJiaB?=	NYXrXlJTTE2VTx?=	MYfJcoNz\WG\|ZTDv[kBxdGG\|bXGgcYVu[nKjbnWg[ZhxemW\|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>	MX:yOFE5PDJzMx?=
BCRP-MDCK2	MonmSpVv[3Srb36gRZN{[Xl?	MXGxMlgh\|ryP	NUfsVGhDPzJiaB?=	NGj1eFlFVVOR	NUnV[XVsWmWmdXP0bY9vKG:oIIDsZZNu[SCvZX3idoFv\SCneIDy[ZN{cW:wIH;mJGJEWlBiZYjwdoV{e2mwZzDy[ZBwenSncjDn[Y5mKEeIUB?=	MX2yOFE5PDJzMx?=
MDCK	MX3DfZRwfG:6aXOgRZN{[Xl?		MXq3NkBp	NGXre45FVVOR	M1T0TmdKPTB;MT60OUDPxE1?	NG[xOIYzPDF6NEKxNy=>
MDCK2	NFTWRo5HfW6ldHnvckBCe3OjeR?=	NXPV[2VmOS56IN88US=>	MXq3NkBp	NELxRoNFVVOR	MUDJcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	NXnMe3FWOjRzOESyNVM>
A431	Ml\tR5l1d3SxeHnjJGF{e2G7		M{nk[lczKGh?	NHXYeY1FVVOR	Mn3MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	MWKyOFQyOTF{Mx?=
Calu3	NGjUfIxEgXSxdH;4bYMhSXO\|YYm=		NFLjPIQ4OiCq	M4X6T2ROW09?	NXvPOG9zS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GudUOgZ4VtdHNiZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCwMlk6KM7:TR?=	M1X3c\|I1PDFzMUKz
KB	Mn\QT4lv[XOnIFHzd4F6	M4fPTlExKM7:TR?=	MkX2NUBp	NILsT4pFVVOR	MX\Jcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6wNlUh\|ryP	Mnn5NlQ1OTFzMkO=
BEAS2B	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\uU5c2OCEQvF2=	M16xZVczKGh?	M3L3dmROW09?	NWjyXZRHUUN3ME2xN{46PCEQvF2=	MkLoNlQ3ODd3OUG=
NCI-H1975	MnjkSpVv[3Srb36gRZN{[Xl?	MUGxNFAh\|ryP	NH\M[HUyPTBibXnu	NXS0elJ7TE2VTx?=	NGfUc5BKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	MXWyOFYxPzV7MR?=
Hela	NX;Z[FUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV[yOEBp	NWWwPYtOTE2VTx?=	NXXhXGsyUUN3ME2yMlY4KM7:TR?=	M32xZVI1PzNzMkix
HepG2	NIezeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{ThTFI1KGh?	M2n2OGROW09?	MVvJR\|UxRTZwNEKg{txO	NULGOXlNOjR5M{GyPFE>
Sf9	MXzLbY5ie2ViQYPzZZk>		MWSxNEBucW5?	NUPQcJJRTE2VTx?=	M3jCXGlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCqaYOteIFo\2WmIFXHSnIhMGGvaX7vJIFkcWRiNkS1MVEyQDZrIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	MXOyOFc{OTJ6MR?=
SW620	NYLjc3ZHS3m2b4TvfIlkKEG\|c3H5		NI\5U\|Q1QCCq	NFi1bWJFVVOR	Ml;ETWM2OD1{OD6yJO69VQ>?	MnjoNlQ6ODB3OUS=
HCC827	NVviZXJSTnWwY4Tpc44hSXO\|YYm=	NV;VZlhzOC53IN88US=>	NF\EOWszKGh?	MWjEUXNQ	M{LEeoRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:w	M2f6dlI{QTl\|M{K4
HCC827	MUTGeY5kfGmxbjDBd5NigQ>?	M17ROVAvPSEQvF2=	NYrrcmtsOiCq	NVPi[3NNTE2VTx?=	M{n5UIRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	NWXR[29SOjN7OUOzNlg>
HCC827	NYL0WndSS3m2b4TvfIlkKEG\|c3H5	MVKwMlUh\|ryP	M3TpTFczKGh?	MlzDSG1UVw>?	MV3oZZMhdm9iY4n0c5RwgGmlaYT5	NGS2N2ozOzl7M{OyPC=>
NCI-H1975	MX;GeY5kfGmxbjDBd5NigQ>?	NHL1W20yOCEQvF2=	NX20dXU2QCCq	M{HFbGROW09?	M1LQZ4Rw\XNibn;0JIlvcGmkaYTpJGVITlJiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	NEHoVnEzOzFzNkG2PC=>
A431	M4fCW2tqdmG\|ZTDBd5NigQ>?	MojYNUDPxE1?	Moi5NUBp	MUDEUXNQ	M4jFcohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	MX[yOFkxODV7NB?=
LNCaP	NG[3dHdHfW6ldHnvckBCe3OjeR?=	MnL4NVAh\|ryP	M4XvS\|JpKG:{IESgbC=>	MXXEUXNQ	M2fnU4Rw\XNibn;0JIlvcGmkaYSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCrbX31co9xfXKrZnnl[EBndGGpLYTh[4dm\CCEbYigZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcOzKSXVHUVC=>	MlvONVg3Pjd\|MUK=
H1975	NIHUW5FMcW6jc3WgRZN{[Xl?	MkH0NUDPxE1?	NIfZW2gzPCCq	MWnEUXNQ	NYGzN3BP\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	MUCyOFYxPzV7MR?=
H1975	M1e1VGZ2dmO2aX;uJGF{e2G7	MVWxJO69VQ>?	MUmyOEBp	NVTGPGFITE2VTx?=	NVrleotP\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	MXqyOFYxPzV7MR?=
HCC827	NXjNT3FxU2mwYYPlJGF{e2G7	NILUU48xNjFzIN88US=>	NWO5e29jOSCq	NFv2[YhFVVOR	NHHMNXJp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjc4Pld5Nm\CCjczDy[YNwfmW{eTDv[kBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36=	NI\uS\|MzPDF{NEi5PC=>
H1975	NEflPVFMcW6jc3WgRZN{[Xl?	MUewMlM{KM7:TR?=	NHPx[I8zKGh?	MnXxSG1UVw>?	M{fB[4Rw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCU1RicHjvd5Bpd3K7bHH0bY9v	Ml3FNlQyOjR6OUi=
H1975	MlTxT4lv[XOnIFHzd4F6	M3X3PVAvOzNizszN	MWOyJIg>	NU\ZfVdZTE2VTx?=	M4r1RoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NGPsZnMzPDF{NEi5PC=>
H1975	NH;ad2ZMcW6jc3WgRZN{[Xl?	MUSwMlM{KM7:TR?=	NHXuN\|YzKGh?	NVLheXpZTE2VTx?=	NEDsPVZld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	NEWxS5kzPDF{NEi5PC=>
H1975	NE\IRmdMcW6jc3WgRZN{[Xl?	M1f2fFAvOTJ3IN88US=>	MUCyOEBp	MV7EUXNQ	M2HOR4Rw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MXiyNlM{QTN2Mh?=
H1975	NHmzeZdMcW6jc3WgRZN{[Xl?	MWSwMlUh\|ryP	NYXmeGNbOjRiaB?=	NHnwbmZFVVOR	NFuwU4Jld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	MY[yNlM{QTN2Mh?=
H1975	MlHZT4lv[XOnIFHzd4F6	NEOzZW0xNjVizszN	M4Kx[FI1KGh?	M3;kOWROW09?	MULkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NELncmIzOjN\|OUO0Ni=>
MIAPaCa2	NGPkc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TsPFIvPSEQvF2=	MUK3NkBp	MkHQSG1UVw>?	MofDbIF{KG6xIHfyc5d1cCCrbnjpZol1cW:w	MXOyNFQ3PjV3NR?=
MIAPaCa2	M3vPXmN6fG:2b4jpZ{BCe3OjeR?=	MlTNNUDPxE1?	NEXKbngyOCCm	NIrV[ZNFVVOR	M3\XWohieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	NVPFUVVnOjB2Nk[1OVU>
MIAPaCa2	M2XhZmFxd3C2b4Ppd{BCe3OjeR?=	MlXSNVAh\|ryP	NES4TZEzPGhib4KgOFghcA>?	MoDsSG1UVw>?	NFexRm9ld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MnX2NlA1PjZ3NUW=
MIAPaCa2	Moi4RZBweHSxc3nzJGF{e2G7	MWKyNEDPxE1?	NUnjeHM1OjRiaB?=	MXjEUXNQ	NUnFO49K\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	NUPpcpROOjB2Nk[1OVU>
EoL-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXSwUo9sUUN3ME21MlE4KG6P	NXXqUHlPW0GQR1XS
NCI-H720	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\qRolKSzVyPUK2MlkzKG6P	MmXJV2FPT0WU
NCI-SNU-5	NWPIfGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPYV\|c6UUN3ME2yPE4yQSCwTR?=	MU\TRW5ITVJ?
EW-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUexeJZqUUN3ME20Ok4xPCCwTR?=	M4HtSHNCVkeHUh?=
HCC2218	M3ywPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFflbJhKSzVyPUWwMlU6KG6P	NGTkfnlUSU6JRWK=
HuO-3N1	NXT5SGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTV4LkC5JI5O	MmLjV2FPT0WU
DB	NHXQSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\rcoZ3UUN3ME22NE46PiCwTR?=	Mn\QV2FPT0WU
HSC-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTITWM2OD14MT61N{BvVQ>?	NV;RToROW0GQR1XS
DOK	M2fxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnJUWFKSzVyPUmzMlYzKG6P	MWHTRW5ITVJ?
H9	NHfhb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV24NWluUUN3ME2xN\|cvOiCwTR?=	MWrTRW5ITVJ?
NCI-H292	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1m2SWlEPTB;MU[yMlY3KG6P	MYjTRW5ITVJ?
HSC-2	NXHxU3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MniwTWM2OD1zNkWuOVchdk1?	NVLuTW04W0GQR1XS
LU-65	NWrESoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXnXXJKSzVyPUG2Ok43OSCwTR?=	M{TtUnNCVkeHUh?=
BV-173	NYnlS3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHCTWM2OD1zOE[uOVUhdk1?	NFHiV3JUSU6JRWK=
LB2241-RCC	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzYTWM2OD1zOUSuPVMhdk1?	NH36OIRUSU6JRWK=
KG-1	NYmzNIxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnRTWM2OD1{MESuN\|Qhdk1?	MYrTRW5ITVJ?
CHL-1	Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3rb5RKSzVyPUKwPE42OSCwTR?=	M2HMZnNCVkeHUh?=
KYSE-140	NWnpeoxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jUPGlEPTB;MkC5Mlk3KG6P	NGLRTVhUSU6JRWK=
DU-145	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi0cVlKSzVyPUKxPU4xPCCwTR?=	NIPzVW1USU6JRWK=
EW-13	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJ{NT6xJI5O	MkHXV2FPT0WU
KYSE-450	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLzXlVvUUN3ME2yOFcvQTJibl2=	NG[4NVlUSU6JRWK=
CAL-72	M3zMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD0dXRFUUN3ME2yOlgvPzNibl2=	M3e4NHNCVkeHUh?=
MEG-01	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfHUJBKSzVyPUK3Ok44PiCwTR?=	M{exRnNCVkeHUh?=
HCE-T	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Lu[WlEPTB;Mke5Mlc6KG6P	M3raNXNCVkeHUh?=
NCI-SNU-1	NF3vVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDKelZoUUN3ME2yPFMvOzJibl2=	NIe3d2pUSU6JRWK=
CAL-27	NEHD[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33WVGlEPTB;Mki5MlA5KG6P	NWLmPWZ6W0GQR1XS
BALL-1	M3rh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJ7Nz60NkBvVQ>?	M1fjOXNCVkeHUh?=
SBC-1	NWrwc3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jpR2lEPTB;M{C3Mlc6KG6P	M4\tfXNCVkeHUh?=
CAL-54	NFLLZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjEVINKSzVyPUOxNU4zOyCwTR?=	NV;ZWHJwW0GQR1XS
TI-73	NEP0bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rJN2lEPTB;M{GyMlc2KG6P	MnG2V2FPT0WU
P12-ICHIKAWA	M4\rZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn63TWM2OD1\|MkiuNFYhdk1?	MWfTRW5ITVJ?
ACHN	NWHCO\|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXy4RXdCUUN3ME2zN\|EvPCCwTR?=	NGf2SJpUSU6JRWK=
PC-14	NIXZ[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzyUVNKSzVyPUOzN{41OSCwTR?=	MnHkV2FPT0WU
HCC1806	NUfWfo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjCT4xKSzVyPUOzO{42OSCwTR?=	M3HaeXNCVkeHUh?=
SK-MEL-24	NGG5VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTwVIZbUUN3ME2zN\|cvQDdibl2=	M4LDTHNCVkeHUh?=
A4-Fuk	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTN3MD6wNkBvVQ>?	NUThc3ZxW0GQR1XS
ECC10	NYjnW3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq1TWM2OD1\|NUKuPVYhdk1?	NYPJR4VTW0GQR1XS
KASUMI-1	NIHaZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TTV2lEPTB;M{[2Mlc{KG6P	M1Xw[3NCVkeHUh?=
CAL-33	M2r3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLSTWM2OD1\|N{CuPUBvVQ>?	NWPNZ\|I1W0GQR1XS
MDA-MB-175-VII	NFXaUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN5OD64PEBvVQ>?	NGHLe4hUSU6JRWK=
NUGC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\UWXdKSzVyPUSwNU45OSCwTR?=	MXPTRW5ITVJ?
KY821	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PQ[mlEPTB;NEC4MlU4KG6P	M3vXNHNCVkeHUh?=
CTB-1	NYC5[XBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHiTWM2OD12MkSuOEBvVQ>?	NVu0d3NHW0GQR1XS
DoTc2-4510	M33IdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXqbZF1UUN3ME20OFIvOTJibl2=	MW\TRW5ITVJ?
EFO-27	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjndYxoUUN3ME20OVQvPzRibl2=	MULTRW5ITVJ?
BPH-1	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDrTWM2OD12OUGuNVYhdk1?	MWrTRW5ITVJ?
KYSE-270	NES3eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3VTWM2OD12OUiuOlUhdk1?	M2r6cHNCVkeHUh?=
HO-1-N-1	NVHWZYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qxZmlEPTB;NUC5MlI2KG6P	MWHTRW5ITVJ?
SK-MEL-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDsc4VYUUN3ME21NVAvQTlibl2=	MnvoV2FPT0WU
MOLT-13	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7M[GdlUUN3ME21NVQvQDJibl2=	M3zF[HNCVkeHUh?=
TK10	NYn4eXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\UO2lEPTB;NUG1MlEyKG6P	NWTOT4lGW0GQR1XS
HN	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTVzNz6zPEBvVQ>?	M2nw[HNCVkeHUh?=
SCC-15	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDyTWM2OD13MkWuOlghdk1?	NHHMRphUSU6JRWK=
NCI-H358	NH;YPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nD[WlEPTB;NUK3MlY3KG6P	Ml7BV2FPT0WU
KYSE-180	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDYR3VKSzVyPUWzNE43OiCwTR?=	M4XGXnNCVkeHUh?=
NCI-H82	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TT[mlEPTB;NUSwMlUhdk1?	MonoV2FPT0WU
NB7	NYPoWnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLkTWM2OD13NE[uN\|Ihdk1?	NILheGlUSU6JRWK=
DSH1	NGHFNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTV4Nj64PEBvVQ>?	NYDM[JJmW0GQR1XS
RS4-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYX2doRrUUN3ME21OlgvPTlibl2=	NVL0c\|VYW0GQR1XS
CAN	NETvNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTV6MD63OkBvVQ>?	NFn3[2pUSU6JRWK=
Ca9-22	NFnodHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrjSYNwUUN3ME21PFgvPjRibl2=	NWLvXmVOW0GQR1XS
CAL-39	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTV7Nj6zJI5O	NGfHO\|lUSU6JRWK=
NCI-H1623	M1W2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vyUGlEPTB;NUm5MlM3KG6P	NG\LSWRUSU6JRWK=
FADU	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLvVYdKSzVyPU[wOE43QSCwTR?=	MYrTRW5ITVJ?
NB69	NV[3RZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTZzND6zOUBvVQ>?	NHXMeFZUSU6JRWK=
Ramos-2G6-4C10	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzoUWhKSzVyPU[yNU41PiCwTR?=	Mnu5V2FPT0WU
LB1047-RCC	M33wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZ{NT6yPUBvVQ>?	MV;TRW5ITVJ?
MV-4-11	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fvemlEPTB;NkK3Mlchdk1?	NWK1UIFoW0GQR1XS
DBTRG-05MG	NHPuR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPTTWM2OD14M{KuNlghdk1?	NH3oVG1USU6JRWK=
ME-180	NVX5V5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLuPWFYUUN3ME22N\|IvQSCwTR?=	NX7YT4doW0GQR1XS
NBsusSR	NGPxbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZ2Nj61NkBvVQ>?	MVTTRW5ITVJ?
COR-L105	NHOyU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX1TWM2OD14NkKuOVMhdk1?	MULTRW5ITVJ?
ETK-1	NFvLW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTDO5pTUUN3ME22OlIvPTlibl2=	MmXsV2FPT0WU
L-363	NEDTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Xtc2lEPTB;NkexMlk1KG6P	NEi0d\|dUSU6JRWK=
LU-134-A	NVTMem51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTjTWM2OD15MUmuNFkhdk1?	NYToUnBWW0GQR1XS
NCI-H1770	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT6TWM2OD15MkKuOEBvVQ>?	M3;DbXNCVkeHUh?=
HAL-01	NHvkdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTd\|ND63NUBvVQ>?	MUPTRW5ITVJ?
COLO-684	M4mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17tZWlEPTB;N{WzMlAyKG6P	NX72fm9IW0GQR1XS
TE-6	NFTXcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTd4ND6zNUBvVQ>?	MX7TRW5ITVJ?
A431	NV6wWZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPkOXBKSzVyPUe4NE4xPCCwTR?=	M1vzXnNCVkeHUh?=
LU-135	NUDFe4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;3fGlEPTB;N{izMlA{KG6P	NG\ORXZUSU6JRWK=
EC-GI-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH36XHVKSzVyPUe4PE42OiCwTR?=	MoHCV2FPT0WU
TE-12	NIHTdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVyxUow3UUN3ME24NlEvOTFibl2=	NVG2bWwzW0GQR1XS
LoVo	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\HSVFHUUN3ME24OVkvODZibl2=	NFzDbZNUSU6JRWK=
23132-87	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfmfmpKSzVyPUi2OE4zQCCwTR?=	M3r4UnNCVkeHUh?=
AU565	NFPhT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\rTWM2OD16NkmuOkBvVQ>?	NEizdG1USU6JRWK=
DEL	NHHEUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDVTWM2OD16N{euOlUhdk1?	M2XsO3NCVkeHUh?=
COR-L88	NVz1SIU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPlV4tKSzVyPUi4Nk4zPiCwTR?=	M4LpVnNCVkeHUh?=
NCI-H2126	M{nQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIe0bYhKSzVyPUi4Nk45OyCwTR?=	M2TkT3NCVkeHUh?=
CAPAN-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDJ[lVHUUN3ME24PFMvOjlibl2=	NYT1Z3ZoW0GQR1XS
BT-474	M2jzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rLdGlEPTB;OUO4MlE1KG6P	MVzTRW5ITVJ?
BHY	NH;kUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfmTGs5UUN3ME25O\|UvPDhibl2=	M4fwbHNCVkeHUh?=
HT-3	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[0Z5J7UUN3ME25PFIvPDFibl2=	NYThPJdRW0GQR1XS
SK-NEP-1	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TuNmlEPTB;OUi5MlQ1KG6P	NG\HfopUSU6JRWK=
MS-1	NXTjW2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLSfpBIUUN3ME25PVQvPjlibl2=	MUfTRW5ITVJ?
DOHH-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7aWmlDUUN3ME2xMlAxODJzIN88US=>	MV3TRW5ITVJ?
NCI-H1304	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTFwMEG2OFMh\|ryP	MVjTRW5ITVJ?
EM-2	M2XRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7OTWM2OD1zLkCzNFE3KM7:TR?=	M4Kxb3NCVkeHUh?=
MHH-PREB-1	M{DpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFwMEi0OVEh\|ryP	MV3TRW5ITVJ?
KU-19-19	NX[3OoE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DTWWlEPTB;MT6wPFU1OSEQvF2=	NXPNPJh2W0GQR1XS
NCI-H1648	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHSN4pKSzVyPUGuNVA3OTZizszN	MVrTRW5ITVJ?
MKN1	NGSwS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwMkG5PFch\|ryP	MXPTRW5ITVJ?
SNU-449	NXj3eYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXPTWM2OD1zLkKyNlA5KM7:TR?=	NGW1SnVUSU6JRWK=
OAW-42	NYmzc49uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rZbGlEPTB;MT6yO\|gzPSEQvF2=	Mn3uV2FPT0WU
769-P	NFu2cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwMke5NVgh\|ryP	MnvEV2FPT0WU
SW1088	NFr3ZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTFwMkm2NFch\|ryP	NYH1b3ZWW0GQR1XS
GCIY	M3qxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfyVnpKSzVyPUGuN\|AyOzJizszN	M4LXdnNCVkeHUh?=
CTV-1	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFwM{C4JO69VQ>?	NGHVRYRUSU6JRWK=
NCI-H1092	M2n2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1uxUWlEPTB;MT6zNFg2KM7:TR?=	NXr6ZmpqW0GQR1XS
NKM-1	NVnpc5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwM{K1PVch\|ryP	M1nYTnNCVkeHUh?=
NCI-H1650	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFwM{O0PFIh\|ryP	M4DGO3NCVkeHUh?=
SW954	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTFwM{SwOFgh\|ryP	NGW1PYxUSU6JRWK=
SW48	NUPWRlR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFwM{[2NVgh\|ryP	MlS5V2FPT0WU
SK-N-DZ	NGDyfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwM{[5OFch\|ryP	NGDw[pZUSU6JRWK=
KMOE-2	NXn2T21xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LWN2lEPTB;MT6zPVgyPSEQvF2=	NWna[JRGW0GQR1XS
NB5	NInLcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vCUGlEPTB;MT60NFg6PCEQvF2=	M1npZnNCVkeHUh?=
CCRF-CEM	M3vxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFwNEGxNUDPxE1?	M{m4d3NCVkeHUh?=
RH-1	NFi1dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTETWM2OD1zLkSxNVM3KM7:TR?=	M4DjZnNCVkeHUh?=
NCI-H526	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XR[GlEPTB;MT60N\|gzPiEQvF2=	M322e3NCVkeHUh?=
697	NYT3cHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTRTWM2OD1zLkS0NVA1KM7:TR?=	NYGyXo5FW0GQR1XS
J82	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\ZZmlEPTB;MT60OVc3PiEQvF2=	MWPTRW5ITVJ?
BE-13	NIq2eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;WN2tFUUN3ME2xMlUxPjdzIN88US=>	M4OyVnNCVkeHUh?=
SAS	NUnCWXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH5e45HUUN3ME2xMlUyPjJ{IN88US=>	NU\4TZp[W0GQR1XS
SCC-25	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3u1XWlEPTB;MT61NlMzOiEQvF2=	MYjTRW5ITVJ?
LAMA-84	NWPBT4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHR[plFUUN3ME2xMlU{QDF3IN88US=>	Mnf2V2FPT0WU
HSC-3	M1rsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvjPIVKSzVyPUGuOVQ{QCEQvF2=	NHjjcYFUSU6JRWK=
BT-549	NGSxN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwNUi3OFch\|ryP	MlvwV2FPT0WU
ML-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvLRoN6UUN3ME2xMlY1ODJ7IN88US=>	NES2[XlUSU6JRWK=
BB30-HNC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\pcWlEPTB;MT62PFk4OiEQvF2=	NFvu[XNUSU6JRWK=
PANC-03-27	NUjoeI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGK0RmNKSzVyPUGuO\|AyOzlizszN	NHrxT\|NUSU6JRWK=
COLO-678	NU\xbJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33XZmlEPTB;MT63N\|Q1PCEQvF2=	NUDK[Y9JW0GQR1XS
NCI-H1666	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTFwN{S3NFQh\|ryP	NEPxPG5USU6JRWK=
NCI-H209	NE\PTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PnPGlEPTB;MT63O\|I3QSEQvF2=	M1W5V3NCVkeHUh?=
EPLC-272H	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPBOoxKSzVyPUGuPFU2PDlizszN	NF3zUlNUSU6JRWK=
OMC-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDoTWM2OD1zLkm5PFg5KM7:TR?=	M{DYR3NCVkeHUh?=
HCC70	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzEUVhSUUN3ME2yMlAxQDF3IN88US=>	NXvpd4xWW0GQR1XS
CAL-12T	NFj3W\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJwMEG4OlEh\|ryP	MYjTRW5ITVJ?
TGBC24TKB	M17zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf6Um5mUUN3ME2yMlAzQTZzIN88US=>	Mk[0V2FPT0WU
EKVX	NW\Pb5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPzTWM2OD1{LkC0PVM6KM7:TR?=	M4\IOHNCVkeHUh?=
SW1116	NEnTeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPzTWM2OD1{LkC2NFA6KM7:TR?=	MUDTRW5ITVJ?
NCI-H2009	NF33UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwME[yNVQh\|ryP	Mn2zV2FPT0WU
RPMI-8866	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS2TWM2OD1{LkC4OFgyKM7:TR?=	NV\mdIxTW0GQR1XS
KARPAS-45	NV\5SplIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJwMUK0O\|kh\|ryP	NHSyfXJUSU6JRWK=
RXF393	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLDTWM2OD1{LkGzNFM3KM7:TR?=	Mof3V2FPT0WU
786-0	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTzTWM2OD1{LkG4OFA3KM7:TR?=	MXLTRW5ITVJ?
SCC-4	M4j1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTJwMkG3O\|Yh\|ryP	NUXqcI5VW0GQR1XS
BT-20	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2j3[mlEPTB;Mj6yOlc1PCEQvF2=	NVW3ZYVTW0GQR1XS
A498	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUWyNFJCUUN3ME2yMlI6PDF3IN88US=>	Ml7IV2FPT0WU
IGROV-1	M4\vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJwM{GyN\|ch\|ryP	MUXTRW5ITVJ?
JVM-3	NHW4b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mme3TWM2OD1{LkO0OlQ{KM7:TR?=	M{DtWnNCVkeHUh?=
NCI-H2170	M13FN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWOyRZQzUUN3ME2yMlM1Pzh\|IN88US=>	MnzjV2FPT0WU
EW-18	NVe0RZQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DtN2lEPTB;Mj6zOVQ4OSEQvF2=	M4i2SnNCVkeHUh?=
KU812	NVfySFl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWOxUnZIUUN3ME2yMlM3Pzd7IN88US=>	M{KzZ3NCVkeHUh?=
NY	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDtclFKSzVyPUKuN\|czPyEQvF2=	MUjTRW5ITVJ?
HTC-C3	NIPhOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJwNEKyOlch\|ryP	NVuy[HZYW0GQR1XS
CFPAC-1	NHHTboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;HTWM2OD1{LkSzPFY1KM7:TR?=	M1vUSnNCVkeHUh?=
HH	NXi2VJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\0dolQUUN3ME2yMlQ6QDV2IN88US=>	MUPTRW5ITVJ?
MKN7	M37p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O1N2lEPTB;Mj62Nlc1QCEQvF2=	NX20XYxyW0GQR1XS
TE-8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\xcGlEPTB;Mj62N\|Y2OyEQvF2=	NYXEOY5jW0GQR1XS
MC-IXC	M2LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYntOlVpUUN3ME2yMlY1PDV\|IN88US=>	MXHTRW5ITVJ?
DMS-79	NWnue\|RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTJwNkmyPFQh\|ryP	MnHwV2FPT0WU
Detroit562	NG[1SnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK3SopVUUN3ME2yMlY6QDR3IN88US=>	MmTUV2FPT0WU
HuP-T4	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHNTWM2OD1{LkeyPFE5KM7:TR?=	Ml[zV2FPT0WU
QIMR-WIL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rWPGlEPTB;Mj63OVk2OiEQvF2=	M33vfHNCVkeHUh?=
BB65-RCC	NXnxRnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml64TWM2OD1{LkiwO\|E{KM7:TR?=	MmDCV2FPT0WU
PC-3	NXrqVFVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJwOEOzNVch\|ryP	NEXBe\|lUSU6JRWK=
OVCAR-3	NWf2cFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3uwUGlEPTB;Mj64OVU6PCEQvF2=	NH\nfIhUSU6JRWK=
KYSE-510	NWjRWIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnwTWM2OD1{Lki2O\|g3KM7:TR?=	MkSwV2FPT0WU
HC-1	M3HhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2iyOGlEPTB;Mj65OFAyOiEQvF2=	NH7ZdlFUSU6JRWK=
NCI-H1693	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vEeGlEPTB;Mj65OVg6PyEQvF2=	NW\SSZZJW0GQR1XS
DU-4475	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fHeWlEPTB;Mj65PVA2OiEQvF2=	NGf0ZZZUSU6JRWK=
COLO-680N	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPQcYtKSzVyPUOuNFA1QTVizszN	NGC3[pBUSU6JRWK=
MN-60	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;XR2Z1UUN3ME2zMlA1QTd2IN88US=>	M{\uUnNCVkeHUh?=
BCPAP	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPTUY9UUUN3ME2zMlA5Ojl3IN88US=>	NYnlVoYyW0GQR1XS
647-V	NHTISXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTNwMU[yNkDPxE1?	M1W1O3NCVkeHUh?=
HT-1376	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTNwMkC1NFYh\|ryP	NEXQXlhUSU6JRWK=
NCI-H1793	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LBW2lEPTB;Mz6yNVA6QCEQvF2=	NIXuWVVUSU6JRWK=
SW1463	M3LieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHuSWFKSzVyPUOuNlYyQTJizszN	MlvjV2FPT0WU
NCI-H727	NV7qR49wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rJNmlEPTB;Mz6zPFU5PCEQvF2=	NIP2VVFUSU6JRWK=
LB771-HNC	M{LkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoSwTWM2OD1\|LkO5NVI3KM7:TR?=	MXTTRW5ITVJ?
D-542MG	NIHSbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnGdYN3UUN3ME2zMlQ1OjJ{IN88US=>	NYrnWFJ2W0GQR1XS
NTERA-S-cl-D1	M3\YWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnjXGU3UUN3ME2zMlQ1QTV5IN88US=>	MoXQV2FPT0WU
C8166	NGjvUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PLWGlEPTB;Mz60OlUzOSEQvF2=	MYDTRW5ITVJ?
639-V	NVG2OpJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXnOpl{UUN3ME2zMlU4Pzl{IN88US=>	M1jrVXNCVkeHUh?=
TE-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnrUm5QUUN3ME2zMlU6OTZ7IN88US=>	M1S2enNCVkeHUh?=
OAW-28	NX\iend2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\GTWM2OD1\|LkW5OFI3KM7:TR?=	NVjmW5VoW0GQR1XS
SK-LU-1	NF;4S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTNwNkC2OFUh\|ryP	NIHLdHdUSU6JRWK=
CaR-1	M4XPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Tic2lEPTB;Mz62NVA1QCEQvF2=	NVnENHk3W0GQR1XS
A2780	M1f3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonXTWM2OD1\|Lk[0NFg6KM7:TR?=	NHzpTWxUSU6JRWK=
C2BBe1	M2\lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLTTWM2OD1\|Lk[0OFA4KM7:TR?=	M{O3NnNCVkeHUh?=
SK-MES-1	NIPKNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TLbGlEPTB;Mz62OFYyPCEQvF2=	NIK4SmRUSU6JRWK=
PANC-10-05	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LLO2lEPTB;Mz63NlA4OiEQvF2=	MUjTRW5ITVJ?
J-RT3-T3-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLqU4xKSzVyPUOuO\|U1ODZizszN	M{TMVXNCVkeHUh?=
ES4	M3rIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP0UYoyUUN3ME2zMlgzOjh4IN88US=>	MXXTRW5ITVJ?
NCI-H28	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DjS2lEPTB;Mz64Nlk3OSEQvF2=	MWjTRW5ITVJ?
NCI-H1155	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\UTWlEPTB;Mz64OFE2QSEQvF2=	NHvlWpNUSU6JRWK=
KURAMOCHI	NIjEXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTNwOE[wOVYh\|ryP	MY\TRW5ITVJ?
NCI-H69	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnP3TWM2OD1\|LkmwNVc5KM7:TR?=	M4PwUHNCVkeHUh?=
IST-MES1	NHLP[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXOTWM2OD1\|Lkm0NFI6KM7:TR?=	NXuyT\|k{W0GQR1XS
NH-12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3LWXBHUUN3ME2zMlk1OTh5IN88US=>	NG\oV\|ZUSU6JRWK=
JVM-2	M1LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4KyNGlEPTB;Mz65OFc2OiEQvF2=	Ml[2V2FPT0WU
EW-16	NUTDdmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTGb29yUUN3ME2zMlk2PTd5IN88US=>	NHfiTVJUSU6JRWK=
NCI-H441	NUHrS\|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XqWWlEPTB;Mz65O\|AyPCEQvF2=	NES4bHdUSU6JRWK=
RCC10RGB	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS1dFgxUUN3ME20MlAyOjR4IN88US=>	M{[4[HNCVkeHUh?=
TCCSUP	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS5TWM2OD12LkGxNFUh\|ryP	MkXIV2FPT0WU
HL-60	NGKxN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mln0TWM2OD12LkGyNlQyKM7:TR?=	M2XkdnNCVkeHUh?=
EW-11	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{L5[mlEPTB;ND6xN\|I3OSEQvF2=	MU\TRW5ITVJ?
KARPAS-299	M1ThTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrsTWM2OD12LkOxNFE{KM7:TR?=	MYjTRW5ITVJ?
SNU-C2B	NIPE[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jWWWlEPTB;ND6zOFY5PiEQvF2=	NF[zNIpUSU6JRWK=
LU-139	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTsNG1FUUN3ME20MlM4OjR5IN88US=>	MX;TRW5ITVJ?
HCC1937	NVXiUFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LKPWlEPTB;ND6zO\|k6OyEQvF2=	M1XhSnNCVkeHUh?=
GR-ST	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTRwNEOxPEDPxE1?	MnLvV2FPT0WU
SK-OV-3	M{Hkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jKUWlEPTB;ND60OlA1OiEQvF2=	M17ocnNCVkeHUh?=
A172	M{CyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvFZ3VsUUN3ME20MlU2PTJzIN88US=>	MVTTRW5ITVJ?
NB10	NVrrRlJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jmU2lEPTB;ND61PVc5OSEQvF2=	NXL1bJVjW0GQR1XS
P30-OHK	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ixOWlEPTB;ND64NVkzQSEQvF2=	MV\TRW5ITVJ?
KYSE-520	NFHYeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkflTWM2OD12Lki4NFE5KM7:TR?=	M1PqSnNCVkeHUh?=
KNS-62	NGS0V\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfDV25tUUN3ME20MlkxQDB5IN88US=>	NEfabIJUSU6JRWK=
ES1	M1TYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvETWM2OD12Lkm2NFM2KM7:TR?=	MnPnV2FPT0WU
KOSC-2	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHa[3FKSzVyPUSuPVk6PTlizszN	M3Pwb3NCVkeHUh?=
TE-9	M3PWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLrTWM2OD13LkCxOVI2KM7:TR?=	MXjTRW5ITVJ?
NCI-H1838	M3TSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXxTWM2OD13LkCyNFc3KM7:TR?=	NXLaNWN6W0GQR1XS
KP-N-YN	NF7CXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X1emlEPTB;NT6xNlU6OSEQvF2=	MVrTRW5ITVJ?
ALL-PO	NHS5[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\Qd2lEPTB;NT6yNlU5PyEQvF2=	Ml70V2FPT0WU
NOMO-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn63TWM2OD13LkKzNVc3KM7:TR?=	MXXTRW5ITVJ?
CGTH-W-1	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTVwM{i1PFQh\|ryP	MVrTRW5ITVJ?
ATN-1	Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGm0fJlKSzVyPUWuOFEyQDRizszN	NX;3c3VVW0GQR1XS
AGS	NXPhTnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTtTWM2OD13LkS5OlE5KM7:TR?=	NX3MR5psW0GQR1XS
SW13	M4POO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[2TWM2OD13LkWzNlY2KM7:TR?=	MYDTRW5ITVJ?
SW1990	NXjJSZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHlSVFWUUN3ME21MlYzOjh3IN88US=>	NVT0N4pyW0GQR1XS
BFTC-905	M4[xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2C3ZmlEPTB;NT62OVg4QCEQvF2=	NEnpeYFUSU6JRWK=
RMG-I	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn1TWM2OD13Lk[1PVQzKM7:TR?=	NYXiS4JDW0GQR1XS
HD-MY-Z	NH;EepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TQV2lEPTB;NT62PFU5OSEQvF2=	M{DuXXNCVkeHUh?=
HCC1187	M3XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEW1eVVKSzVyPUWuO\|ExOzJizszN	NWDYdHJrW0GQR1XS
HCC2998	NH7EbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jBWWlEPTB;NT63NVg4PyEQvF2=	M{nnbnNCVkeHUh?=
RT-112	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDmTJBjUUN3ME21MlkxOjR3IN88US=>	MmX3V2FPT0WU
CAKI-1	NEn0WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXrTWM2OD14LkCwPVg2KM7:TR?=	NYLMZWhJW0GQR1XS
HDLM-2	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LMN2lEPTB;Nj6wNVQ5QSEQvF2=	M{jIZnNCVkeHUh?=
TE-10	M3XrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHa[WxKSzVyPU[uNFQ5OzNizszN	M{\vRnNCVkeHUh?=
KE-37	NETKWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXy1XFA6UUN3ME22MlA4OjV6IN88US=>	MU\TRW5ITVJ?
RCM-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XtU2lEPTB;Nj6wO\|cyQSEQvF2=	MljwV2FPT0WU
Mewo	NVGyOotnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;5eFBGUUN3ME22MlEyPDh5IN88US=>	M1fnOHNCVkeHUh?=
L-428	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS2WXFlUUN3ME22MlE5ODN5IN88US=>	M{ftbXNCVkeHUh?=
8-MG-BA	M{jVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTZwMUmzO\|kh\|ryP	MYDTRW5ITVJ?
SK-MEL-28	M1WxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPKU\|BKSzVyPU[uNlA6PjdizszN	Ml3kV2FPT0WU
VA-ES-BJ	NX\tfWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;MSmlEPTB;Nj6zNFQ3OiEQvF2=	NIXl[ldUSU6JRWK=
CAL-120	NVLs[YlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn3OoZjUUN3ME22MlQ2OTZ{IN88US=>	MX;TRW5ITVJ?
GAMG	NIHGcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\GTWM2OD14LkWwOlIh\|ryP	Mn7iV2FPT0WU
MSTO-221H	NHHadplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnOTIRiUUN3ME22MlUyOTdizszN	MVfTRW5ITVJ?
GCT	NF7FdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTZwNUOzPFch\|ryP	M1LI[nNCVkeHUh?=
SH-4	NXnmUlBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn31TWM2OD14LkW4PFQ1KM7:TR?=	NXiyeXV5W0GQR1XS
Calu-3	NVXqNVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LxdGlEPTB;Nj62OVU3QCEQvF2=	MmP5V2FPT0WU
SK-HEP-1	M3;tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvyTWM2OD14LkexO\|U{KM7:TR?=	MlHwV2FPT0WU
PFSK-1	NWPDe3dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInzR\|lKSzVyPU[uO\|M1PzhizszN	MUjTRW5ITVJ?
NB12	NITLe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTZwN{i0NFQh\|ryP	M2TuTnNCVkeHUh?=
A388	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzCTWM2OD14Lki5OVIh\|ryP	NH\UfJNUSU6JRWK=
KLE	M4GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[4THJKSzVyPU[uPVY2OTZizszN	M17abHNCVkeHUh?=
TE-11	NET3T4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHESINKSzVyPUeuNFQ6PjdizszN	NEiyUoZUSU6JRWK=
NCI-H2405	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XyRWlEPTB;Nz6wPFM6OyEQvF2=	NEDSWIxUSU6JRWK=
OVCAR-4	NEPkUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjITWM2OD15LkG1N\|Uh\|ryP	MXPTRW5ITVJ?
KP-N-YS	M3zBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDkdYxKSzVyPUeuNVgyPCEQvF2=	MnjoV2FPT0WU
NOS-1	NYjaSY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPpTWM2OD15LkK1PFI5KM7:TR?=	MnK2V2FPT0WU
DMS-114	M1XydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3oTW01UUN3ME23MlI6PjNzIN88US=>	NGnjSXZUSU6JRWK=
NCI-H2030	NWPPWW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnCTWM2OD15LkOzOlk5KM7:TR?=	Mo\sV2FPT0WU
HEL	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1G3Z2lEPTB;Nz6zO\|UzOSEQvF2=	NGjvfItUSU6JRWK=
CAL-62	NEe3W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTdwM{m4OlYh\|ryP	M320[HNCVkeHUh?=
COLO-668	NVrNV\|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzKTWM2OD15LkSzPVY4KM7:TR?=	M4LFXXNCVkeHUh?=
SKG-IIIa	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv1XYlnUUN3ME23MlQ2OzhzIN88US=>	NGfZO5NUSU6JRWK=
HCC1419	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWiycFNzUUN3ME23MlQ3QDN\|IN88US=>	NV;qSpFGW0GQR1XS
OS-RC-2	NIjRR\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD0TWM2OD15LkS5PFk1KM7:TR?=	MoT1V2FPT0WU
COLO-829	NXPhSY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLyTWM2OD15Lk[2OFY{KM7:TR?=	MWLTRW5ITVJ?
NB13	NWrSRpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfPTlZrUUN3ME23MlgzPjZ5IN88US=>	MXvTRW5ITVJ?
DK-MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTdwOEOyNFEh\|ryP	Ml3SV2FPT0WU
SHP-77	M3TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fpbWlEPTB;Nz64OlY2OyEQvF2=	M{fVSnNCVkeHUh?=
NCI-H661	M4LmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nwOmlEPTB;OD6wOVg3PyEQvF2=	Mnm4V2FPT0WU
AM-38	NYXwSphWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTuTnRjUUN3ME24MlE3OjhizszN	MkLHV2FPT0WU
VM-CUB-1	NHv5NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\DVZVKSzVyPUiuNVcxOjlizszN	M36xO3NCVkeHUh?=
KYSE-70	NH7TemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\HXW1FUUN3ME24MlE6PzZzIN88US=>	Mk\lV2FPT0WU
5637	NHP3dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRThwM{GwOVUh\|ryP	MmPrV2FPT0WU
TGBC11TKB	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHq3c4pKSzVyPUiuOFYyPjRizszN	NIW1bYNUSU6JRWK=
EGI-1	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkKzTWM2OD16Lk[wNFg5KM7:TR?=	M2j2RXNCVkeHUh?=
D-392MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrVV4xSUUN3ME24MlY3OjF2IN88US=>	MkexV2FPT0WU
A673	M3npeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRThwNke2NVEh\|ryP	MkjvV2FPT0WU
COLO-792	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;5TWM2OD16Lke0PVQ3KM7:TR?=	MYrTRW5ITVJ?
NCI-H1792	NXrqXHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWe1WmFLUUN3ME24Mlg5QTB\|IN88US=>	M1iwc3NCVkeHUh?=
LS-1034	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLhOW9LUUN3ME24Mlk1PjV{IN88US=>	NXz3OlRCW0GQR1XS
D-566MG	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTlwMEG4NUDPxE1?	M175bXNCVkeHUh?=
NCI-H226	NHfvdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:wTWM2OD17LkC5JO69VQ>?	NE[xeopUSU6JRWK=
ChaGo-K-1	M3;Yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHvTWM2OD17LkGwOVc6KM7:TR?=	MWLTRW5ITVJ?
NCI-H2228	NHOxPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XDS2lEPTB;OT6xNVA5OSEQvF2=	MXvTRW5ITVJ?
RPMI-8226	NHPCNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn65TWM2OD17LkGxN\|A1KM7:TR?=	MUnTRW5ITVJ?
BFTC-909	NHLLNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjTUHRMUUN3ME25MlE5Ojl5IN88US=>	NHzMOIJUSU6JRWK=
HPAF-II	NEPtU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYizcm1nUUN3ME25MlIzPTF6IN88US=>	NEDQbWxUSU6JRWK=
Capan-2	NVHQflJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi3WFVOUUN3ME25MlQxOTB7IN88US=>	NXnhdIJbW0GQR1XS
IA-LM	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn3elYyUUN3ME25MlQyQTZ4IN88US=>	NV;TXGFQW0GQR1XS
KP-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTVTWM2OD17LkS4PFM5KM7:TR?=	MkLnV2FPT0WU
A101D	NHez[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnnTWM2OD17LkWxO\|E6KM7:TR?=	NHi2c5ZUSU6JRWK=
EFO-21	NXLFUnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnj1TWM2OD17LkW4O\|M2KM7:TR?=	MoW1V2FPT0WU
C32	NXKzSHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;tTWM2OD17Lk[zN\|Qh\|ryP	NFX1VlVUSU6JRWK=
SW837	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPSTWM2OD17Lki0PFIh\|ryP	Mn3CV2FPT0WU
OCI-AML2	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX24e5E6UUN3ME25Mlg3QTZizszN	MYrTRW5ITVJ?
NCI-H1355	NFHOepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTlwOUSwPFgh\|ryP	NIjU[ItUSU6JRWK=
NCI-H2342	NGDYTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLqTWM2OD1zMD6wNVU2KM7:TR?=	MXXTRW5ITVJ?
A204	NFK2V\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7kSnhKSzVyPUGwMlA1PjZizszN	NUDa[3NJW0GQR1XS
CAL-51	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PQ[2lEPTB;MUCuNFg4PyEQvF2=	M1H5W3NCVkeHUh?=
HCE-4	NXPReW5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTFyLkGxNlIh\|ryP	M3Trb3NCVkeHUh?=
NCI-H810	NXi3UllbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDlTWM2OD1zMD6xOVk4KM7:TR?=	MnzPV2FPT0WU
DJM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXzcGRKSzVyPUGwMlE4OzJizszN	MWLTRW5ITVJ?
SK-UT-1	NYe4fI92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfGXJJPUUN3ME2xNE4zPTd2IN88US=>	NVLqfotYW0GQR1XS
U031	NYDVWodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rUcWlEPTB;MUCuNlY5PiEQvF2=	NY\iV2JwW0GQR1XS
YH-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13rSmlEPTB;MUCuN\|A2PyEQvF2=	MorFV2FPT0WU
K5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuxTWM2OD1zMD6zN\|k2KM7:TR?=	MlXvV2FPT0WU
HEC-1	NW\JZ4szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTFyLkSwPFEh\|ryP	M3;uRnNCVkeHUh?=
A2058	M17CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFyLkW0PVEh\|ryP	MlrxV2FPT0WU
SW962	NIHUdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPYUWlKSzVyPUGwMlYzODRizszN	NW\mbppwW0GQR1XS
VMRC-RCZ	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTFyLk[3OFkh\|ryP	NXvoT5FLW0GQR1XS
D-336MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnsfFJKSzVyPUGwMlcxODVizszN	MnzTV2FPT0WU
LXF-289	NGLEZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjQSYkxUUN3ME2xNE44QTZ5IN88US=>	MVPTRW5ITVJ?
SW900	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDVbWhCUUN3ME2xNE45OjJ6IN88US=>	NYPPO\|dCW0GQR1XS
K-562	NXnBfIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\CTWM2OD1zMD64N\|k2KM7:TR?=	MYXTRW5ITVJ?
HCC38	M4[3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvzWpdKSzVyPUGwMlk4OTZizszN	Ml\jV2FPT0WU
SF-295	M4HXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETMU5hKSzVyPUGwMlk6ODJizszN	MVnTRW5ITVJ?
LB831-BLC	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXOWWhFUUN3ME2xNU4zPTV4IN88US=>	MUnTRW5ITVJ?
FTC-133	M4XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFzLkOwPFEh\|ryP	M2rtWXNCVkeHUh?=
HCC1954	NH\FcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P2O2lEPTB;MUGuOFM3KM7:TR?=	MVLTRW5ITVJ?
GOTO	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFzLkWyNFYh\|ryP	MYDTRW5ITVJ?
LS-411N	NHXVfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33MSmlEPTB;MUGuOlExOSEQvF2=	MULTRW5ITVJ?
RPMI-7951	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEL3UGhKSzVyPUGxMlY{PDhizszN	MnvqV2FPT0WU
NCI-H1299	NYnCbYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFzLk[2OFch\|ryP	MkLPV2FPT0WU
MLMA	M1H4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HTSmlEPTB;MUGuOlk6PyEQvF2=	M134T3NCVkeHUh?=
MMAC-SF	NHLmXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPzenlKSzVyPUGxMlczPTJizszN	M4PDNnNCVkeHUh?=
UM-UC-3	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17ifWlEPTB;MUGuO\|QzOSEQvF2=	MUPTRW5ITVJ?
SCC-9	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTFzLkixOVEh\|ryP	M1TwUnNCVkeHUh?=
HOS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDtSVJKSzVyPUGxMlg3QDNizszN	NISw[I1USU6JRWK=
OE19	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvJUXZKSzVyPUGxMlk{PjdizszN	M2HDRXNCVkeHUh?=
Mo-T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTkTWM2OD1zMT65OVQyKM7:TR?=	NXnybll1W0GQR1XS
CAMA-1	NEe5VJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF{LkG2N\|Mh\|ryP	MmK2V2FPT0WU
U-118-MG	NH3tN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrZTWM2OD1zMj6yOFQyKM7:TR?=	MYDTRW5ITVJ?
KS-1	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTF{LkK4N\|Ih\|ryP	NHfSTYhUSU6JRWK=
JAR	NVnsS21OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFS5TZVKSzVyPUGyMlM{PjlizszN	NXPYb\|l2W0GQR1XS
ABC-1	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M173UmlEPTB;MUKuN\|QyKM7:TR?=	M1vHenNCVkeHUh?=
Daoy	NHvDV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTF{LkS1OFIh\|ryP	NHuyZWpUSU6JRWK=
C3A	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPlTWM2OD1zMj61O\|g2KM7:TR?=	M{jRXnNCVkeHUh?=
GT3TKB	NEjZUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nvfGlEPTB;MUKuOlMzPyEQvF2=	MnWwV2FPT0WU
DMS-273	M1zIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTYU2J4UUN3ME2xNk45PjN\|IN88US=>	MnPxV2FPT0WU
G-361	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j3OmlEPTB;MUKuPVEzQSEQvF2=	NYjnW2xyW0GQR1XS
RH-18	NGnC[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jUe2lEPTB;MUOuNlk3OiEQvF2=	M3fDSnNCVkeHUh?=
SN12C	NUP1WmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVq2U4w2UUN3ME2xN{4{QDB6IN88US=>	NFrnXnZUSU6JRWK=
NCI-H1993	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfMTWM2OD1zMz60Nlg2KM7:TR?=	MlzDV2FPT0WU
LOXIMVI	M4fwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;GVWlEPTB;MUOuOlE2OSEQvF2=	NYnJdWpQW0GQR1XS
SK-PN-DW	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrCTWV7UUN3ME2xN{45PDJ5IN88US=>	NWGw[GR1W0GQR1XS
KALS-1	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfQcnNKSzVyPUGzMlg2OjVizszN	M1qxNXNCVkeHUh?=
LAN-6	NXLIXFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DONGlEPTB;MUSuNlU{KM7:TR?=	M4Xhd3NCVkeHUh?=
A549	NIO0XllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF2LkS3NVIh\|ryP	NUnMN4tQW0GQR1XS
RD	NFnpTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnmdVJQUUN3ME2xOE41QDF\|IN88US=>	NV63d\|Y5W0GQR1XS
TGBC1TKB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;1TWM2OD1zND62OlE2KM7:TR?=	MUDTRW5ITVJ?
NCI-H630	M3;oTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljhTWM2OD1zND65OFY4KM7:TR?=	NYjhXYVoW0GQR1XS
MIA-PaCa-2	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKxcG1jUUN3ME2xOE46PjlizszN	NFW3UoNUSU6JRWK=
NCI-H1755	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFWzWlVKSzVyPUG0Mlk6PTNizszN	MV3TRW5ITVJ?
MOLT-4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP1TWM2OD1zNT6wOFk4KM7:TR?=	MYTTRW5ITVJ?
CW-2	NX\3W4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDxWXJKSzVyPUG1MlE1OjFizszN	NXT6ToRtW0GQR1XS
COLO-320-HSR	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkToTWM2OD1zNT61N\|A4KM7:TR?=	NFTWWIVUSU6JRWK=
UMC-11	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmWxTWM2OD1zNT63OVI{KM7:TR?=	NH;qRXRUSU6JRWK=
MCF7	NYnp[nd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC2TWM2OD1zNT64NVQ2KM7:TR?=	NEDVOWhUSU6JRWK=
NCI-H23	NXq0[GhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV76fYJrUUN3ME2xOU45PDN6IN88US=>	M3WwXXNCVkeHUh?=
HuCCT1	M4fybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrVXlZLUUN3ME2xOU45PzRizszN	MVTTRW5ITVJ?
MPP-89	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF3Lkm0NVch\|ryP	MXnTRW5ITVJ?
HT55	NXexRoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3ke\|RKSzVyPUG1Mlk1PzhizszN	NH7kVJJUSU6JRWK=
no-11	M{jvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGThNIdKSzVyPUG1Mlk3PjNizszN	NIPsO4FUSU6JRWK=
GP5d	NIXmUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPqTndSUUN3ME2xOk4zOTh5IN88US=>	M{TNXXNCVkeHUh?=
BHT-101	NXf1[VJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHzeoRKSzVyPUG2MlI1OzlizszN	NVnlN5FmW0GQR1XS
M059J	M{\tOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j2NGlEPTB;MU[uNlg1KM7:TR?=	MnnNV2FPT0WU
D-283MED	M2C3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF4LkSyNFkh\|ryP	NUXabFZ{W0GQR1XS
BEN	M1G4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXZV5RZUUN3ME2xOk42OTV3IN88US=>	MUHTRW5ITVJ?
LB373-MEL-D	NF\TcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zFNWlEPTB;MU[uO\|I{OiEQvF2=	M1PkVnNCVkeHUh?=
MEL-HO	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHGwdIZKSzVyPUG2Mlg5PTRizszN	M2rrbXNCVkeHUh?=
GI-ME-N	M2fwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXr4b3RVUUN3ME2xOk46ODN{IN88US=>	NYn3PHJ{W0GQR1XS
RKO	NXfF[FJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3mwWGlEPTB;MUeuNFc1QCEQvF2=	NVjNc4lrW0GQR1XS
MZ2-MEL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n5cWlEPTB;MUeuNVM{KM7:TR?=	NFnNVnJUSU6JRWK=
NCI-H1573	NULzcXZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF5LkK4NlYh\|ryP	MnnTV2FPT0WU
NCI-H1581	NEHpeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NECwUJRKSzVyPUG3MlQ1OTFizszN	M2jldHNCVkeHUh?=
NCI-H747	NIXRNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDJTWM2OD1zNz61Nlk4KM7:TR?=	MojFV2FPT0WU
SW1783	M{DVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPWd2x{UUN3ME2xO{43PDF3IN88US=>	NX7FV3M5W0GQR1XS
Calu-6	NFOxRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTF5Lk[3PFIh\|ryP	M2LhN3NCVkeHUh?=
SF268	M3Lld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HHRWlEPTB;MUeuOlk3QSEQvF2=	MUPTRW5ITVJ?
ES8	NEn2UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF5Lki1PVMh\|ryP	M2[wS3NCVkeHUh?=
KM-H2	NHnxOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;keodQUUN3ME2xO{46PDFzIN88US=>	NVjWVXpTW0GQR1XS
D-502MG	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF5Lkm4NFgh\|ryP	NFLSU5RUSU6JRWK=
HLE	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEP6fmFKSzVyPUG4MlMyPDhizszN	NXHQXJdxW0GQR1XS
SW982	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDG[oQ3UUN3ME2xPE41ODd3IN88US=>	NXn3OlBWW0GQR1XS
MDA-MB-361	NWOzN5ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF6LkW1PFgh\|ryP	M13SVXNCVkeHUh?=
NCI-H1563	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkCzTWM2OD1zOD63NVI1KM7:TR?=	M1rHfHNCVkeHUh?=
MFE-280	NXS3TnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTEc2R2UUN3ME2xPE44Ojl\|IN88US=>	NFLRPZVUSU6JRWK=
U251	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTu[4dvUUN3ME2xPE44OzR5IN88US=>	M4q2SnNCVkeHUh?=
KNS-42	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH5TWM2OD1zOD64NFE2KM7:TR?=	MV7TRW5ITVJ?
U-266	M2Tqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrXcZhKSzVyPUG4Mlg3PDlizszN	M{PHNnNCVkeHUh?=
OVCAR-8	M1jNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;2PWlEPTB;MUiuPVI4PiEQvF2=	NHq0T5ZUSU6JRWK=
MFH-ino	NFfwTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzpOZJrUUN3ME2xPE46PjZ7IN88US=>	MUnTRW5ITVJ?
D-263MG	NXy1SINlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF7LkCxO\|Ih\|ryP	M3rVd3NCVkeHUh?=
NCI-H1437	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTF7LkC0Olch\|ryP	M33QeHNCVkeHUh?=
NCI-H1048	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HMRWlEPTB;MUmuNlMzPiEQvF2=	M3LOT3NCVkeHUh?=
NCI-H446	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm0Oo5KUUN3ME2xPU4{PTh7IN88US=>	MnG3V2FPT0WU
NCI-N87	NWfGdohDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrlVnVKSzVyPUG5MlU6QTJizszN	M4j2fnNCVkeHUh?=
WM-115	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTF7Lk[3O\|Qh\|ryP	NYTMNm5uW0GQR1XS
HuH-7	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2D6S2lEPTB;MUmuO\|QzOSEQvF2=	MoHHV2FPT0WU
NCI-H650	NGTwNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7jTWM2OD1zOT63OVA5KM7:TR?=	NETr[otUSU6JRWK=
TYK-nu	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PTU2lEPTB;MUmuPFM4QCEQvF2=	M2XJb3NCVkeHUh?=
Becker	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzETWM2OD1zOT64OVQ4KM7:TR?=	MUXTRW5ITVJ?
BB49-HNC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITFXI5KSzVyPUG5MlkzKM7:TR?=	MYfTRW5ITVJ?
HGC-27	M4XLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7RZY1KSzVyPUKwMlE{QTRizszN	MXTTRW5ITVJ?
SiHa	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe1T2NKSzVyPUKwMlM4OTJizszN	NWPJeoZ4W0GQR1XS
LB2518-MEL	NHPqco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJyLkO3N\|kh\|ryP	NWjndlFqW0GQR1XS
TE-5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjmPXBsUUN3ME2yNE44PDh{IN88US=>	NEe5O2hUSU6JRWK=
IST-SL1	NXjkeWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlznTWM2OD1{MD63PFc6KM7:TR?=	M1O5eXNCVkeHUh?=
A375	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnSdVJpUUN3ME2yNU4xPTZ5IN88US=>	MUPTRW5ITVJ?
MC116	M1LVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXueZRKSzVyPUKxMlA4OjNizszN	Ml6xV2FPT0WU
GI-1	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjITWM2OD1{MT6xO{DPxE1?	MWXTRW5ITVJ?
HOP-62	NF3HXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3YTFVKSzVyPUKxMlI4QDRizszN	MUPTRW5ITVJ?
PA-1	M1XBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPiWoZXUUN3ME2yNU4zPzh5IN88US=>	NGnCbZNUSU6JRWK=
HT	NGr2VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH2TWM2OD1{MT60N\|MyKM7:TR?=	Mn\yV2FPT0WU
HUTU-80	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHYT4ZvUUN3ME2yNU41OzN4IN88US=>	M4LzWnNCVkeHUh?=
NCI-H1975	M1LQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXhUpA3UUN3ME2yNU41PjFizszN	Mmi0V2FPT0WU
GAK	NWOzUJdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO4TWM2OD1{MT60PVkh\|ryP	MWDTRW5ITVJ?
SK-N-AS	NUjFc2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTJzLkW2NVkh\|ryP	MXPTRW5ITVJ?
OE33	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v5dGlEPTB;MkGuOlA1PiEQvF2=	M2fwcnNCVkeHUh?=
YKG-1	NHvzeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHHTWM2OD1{MT62OVQ2KM7:TR?=	M1G5R3NCVkeHUh?=
CAL-85	NFfBZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTDTWM2OD1{MT65N\|A2KM7:TR?=	MnqwV2FPT0WU
NCI-H2347	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXyWpc4UUN3ME2yNU46PDJ6IN88US=>	MmDlV2FPT0WU
PANC-08-13	M4jZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX2WlVjUUN3ME2yNk4xOTF7IN88US=>	NIHiOWpUSU6JRWK=
SK-N-FI	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj2TWM2OD1{Mj6zNFc1KM7:TR?=	NGLIeJJUSU6JRWK=
NEC8	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4ewPGlEPTB;MkKuOVA4QCEQvF2=	MUPTRW5ITVJ?
AN3-CA	NYW1[\|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXJc\|hpUUN3ME2yNk43ODh2IN88US=>	MnLZV2FPT0WU
HuO9	NEfUfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG5RmtPUUN3ME2yNk44Ozl4IN88US=>	MlPuV2FPT0WU
COLO-800	NXTI[WtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrLPXJKSzVyPUKyMlc3PTNizszN	NFXPXo1USU6JRWK=
HT-29	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TtXWlEPTB;MkKuPFgzOyEQvF2=	MmrEV2FPT0WU
OC-314	NH;LUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTJ{Lki4OFUh\|ryP	NHe3WYxUSU6JRWK=
G-401	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWi3TpZpUUN3ME2yN{4xPDZ{IN88US=>	MmTqV2FPT0WU
Saos-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1f3fWlEPTB;MkOuOVE5OiEQvF2=	MVnTRW5ITVJ?
UACC-62	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDhVXliUUN3ME2yN{42QDN\|IN88US=>	M17kPXNCVkeHUh?=
D-247MG	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LuTGlEPTB;MkOuO\|k{QSEQvF2=	M1jSOHNCVkeHUh?=
COLO-741	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu3[lJKSzVyPUKzMlk2PjVizszN	Mn\yV2FPT0WU
ES3	NV3leFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfwVY5[UUN3ME2yOE4xODJ\|IN88US=>	MmrRV2FPT0WU
LNCaP-Clone-FGC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJ2LkCyNVEh\|ryP	NVXuZ2JSW0GQR1XS
SW1710	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJ2LkG1NFYh\|ryP	MYjTRW5ITVJ?
LU-99A	NYTBfHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT6d4ZKSzVyPUK0MlE5PDFizszN	MlTBV2FPT0WU
HOP-92	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2q3WWlEPTB;MkSuO\|I2KM7:TR?=	MoKwV2FPT0WU
LS-123	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJ2Lkm2NVQh\|ryP	MVvTRW5ITVJ?
T84	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJ2Lkm3OlUh\|ryP	NHPBU4FUSU6JRWK=
HCT-116	M1HuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJ3LkSxPFYh\|ryP	NUPBSpV[W0GQR1XS
M14	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[2VZNkUUN3ME2yOU41PDR5IN88US=>	NXnaXXR{W0GQR1XS
OCUB-M	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nBfWlEPTB;MkWuOFQ2PiEQvF2=	NEXacFFUSU6JRWK=
MKN45	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXKxdJltUUN3ME2yOU43OzF3IN88US=>	Mm\tV2FPT0WU
LCLC-97TM1	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTJ3LkeyPFUh\|ryP	MW\TRW5ITVJ?
RVH-421	NV7Lc2drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXFXGpmUUN3ME2yOU45OTZzIN88US=>	NHm1WnhUSU6JRWK=
NKS-81-FD	NGTqS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUi3UHRKUUN3ME2yOU46ODJzIN88US=>	MVrTRW5ITVJ?
NCI-H596	NYHPfmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XZeWlEPTB;Mk[uNFQ5PyEQvF2=	NX;tPWxRW0GQR1XS
GB-1	NEjMN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVj2doRzUUN3ME2yOk4yQDd7IN88US=>	Mo\DV2FPT0WU
ZR-75-30	NHLKe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3kTWM2OD1{Nj6yNlk4KM7:TR?=	NU[1W\|NpW0GQR1XS
U-2-OS	NFrU[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nQSGlEPTB;Mk[uN\|c2PyEQvF2=	MXLTRW5ITVJ?
HuP-T3	NX7XfZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoeyTWM2OD1{Nj62NVAzKM7:TR?=	MnLzV2FPT0WU
MOLT-16	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkOxTWM2OD1{Nj62NVY3KM7:TR?=	MmDyV2FPT0WU
U-87-MG	M3TyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zqWmlEPTB;Mk[uO\|Q{QCEQvF2=	MUXTRW5ITVJ?
8505C	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDWVYhjUUN3ME2yOk46OTJ4IN88US=>	M1vjU3NCVkeHUh?=
SK-MEL-3	M3\SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLWTWM2OD1{Nj65PFI5KM7:TR?=	M2OxPHNCVkeHUh?=
COLO-824	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm0[Wc3UUN3ME2yO{4zOTl3IN88US=>	MVXTRW5ITVJ?
EW-1	M1roOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDEW5dHUUN3ME2yO{4{PTV2IN88US=>	MlHuV2FPT0WU
UACC-257	NYHFT2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJ5LkO4NFQh\|ryP	NECwVnlUSU6JRWK=
Hs-578-T	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ5LkWyPVkh\|ryP	MV7TRW5ITVJ?
UACC-893	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\qXGROUUN3ME2yO{43PjNzIN88US=>	Mnq0V2FPT0WU
MHH-NB-11	M{Oz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;TV\|RtUUN3ME2yO{45ODB5IN88US=>	MmLiV2FPT0WU
KYSE-410	NFe0ZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XlNWlEPTB;MkiuNlc4QSEQvF2=	NG\2eW1USU6JRWK=
SF126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrJTWM2OD1{OD63OFM2KM7:TR?=	MVHTRW5ITVJ?
HT-144	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3DTWM2OD1{OT6zN\|YzKM7:TR?=	MmS1V2FPT0WU
SW1573	M1S2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fCbGlEPTB;MkmuN\|UxQSEQvF2=	NXG2XnM{W0GQR1XS
SW620	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rxdWlEPTB;MkmuN\|Y1OSEQvF2=	MkfPV2FPT0WU
SCH	NVjCPYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXrboVzUUN3ME2yPU45QDNzIN88US=>	NXG0NVluW0GQR1XS
EW-22	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNyLkG5Olkh\|ryP	MYXTRW5ITVJ?
H4	M4Difmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTNyLkS2OVQh\|ryP	MYHTRW5ITVJ?
CAS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIT1PZZKSzVyPUOwMlc5PTlizszN	NFTISWdUSU6JRWK=
MG-63	M3LoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHW4c5NKSzVyPUOwMlg1PzhizszN	MX3TRW5ITVJ?
MDA-MB-415	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXZWI5KSzVyPUOxMlE4PTNizszN	NVrZbJBbW0GQR1XS
NCI-H1395	NUT1N3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrVTWM2OD1\|MT6yN\|I5KM7:TR?=	Mnq3V2FPT0WU
Ca-Ski	M3LD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XR[mlEPTB;M{GuN\|E4PyEQvF2=	NFTp[5NUSU6JRWK=
BxPC-3	M1jDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjib2tKSzVyPUOxMlM4OjlizszN	MWLTRW5ITVJ?
A3-KAW	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTNzLkS0O\|Eh\|ryP	MXTTRW5ITVJ?
T-24	M{PTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPNTWM2OD1\|MT63N\|YzKM7:TR?=	NW\PV5pIW0GQR1XS
NCI-H2029	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy2b4xKSzVyPUOxMlc4PjVizszN	M3O0OnNCVkeHUh?=
YAPC	NXvNcII{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTN{LkC0NFch\|ryP	NH3PN\|FUSU6JRWK=
SK-MEL-2	NE\uXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{C3fGlEPTB;M{KuNFUzKM7:TR?=	MoTyV2FPT0WU
LS-513	NGO5UGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPvR2VKSzVyPUOyMlEyQDdizszN	NGi1fI9USU6JRWK=
AsPC-1	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;xTWM2OD1\|Mj6zOlA2KM7:TR?=	MkfBV2FPT0WU
KYSE-150	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfSelNKSzVyPUOyMlM4PzNizszN	M1XCZnNCVkeHUh?=
NCI-H520	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HYemlEPTB;M{KuOFQ5OiEQvF2=	MVXTRW5ITVJ?
JEG-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3oUXdKSzVyPUOzMlA6PzFizszN	NE[zXZdUSU6JRWK=
GMS-10	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHuTWM2OD1\|Mz6zNFA1KM7:TR?=	MlnIV2FPT0WU
HT-1080	NWjhRYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTN\|LkO5JO69VQ>?	MnjIV2FPT0WU
NCI-H1651	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTN\|LkO5OkDPxE1?	MnzJV2FPT0WU
NCI-H2122	NFvYTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHFSZBKSzVyPUOzMlU2PzRizszN	Ml3mV2FPT0WU
ES5	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;vUnFLUUN3ME2zN{44Ojl{IN88US=>	NX\JeVJ1W0GQR1XS
8305C	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfQTVQ5UUN3ME2zN{46QTN5IN88US=>	M1XjTHNCVkeHUh?=
KM12	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jpd2lEPTB;M{SuNFQ4QCEQvF2=	MUjTRW5ITVJ?
HCT-15	NELsOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrjOJRKSzVyPUO0MlEzPyEQvF2=	Mn6wV2FPT0WU
OVCAR-5	NFvPN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX0R3ZKSzVyPUO0MlIyQDJizszN	M3LXWnNCVkeHUh?=
NCI-H2291	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTN2LkK0O\|Ih\|ryP	MoLpV2FPT0WU
CP50-MEL-B	M3fjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TuSWlEPTB;M{SuOlU6OiEQvF2=	MljUV2FPT0WU
C-33-A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\1UI1DUUN3ME2zOE43QDV5IN88US=>	NFH1fFRUSU6JRWK=
NCI-H2452	NI\xXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTN2Lke4PFIh\|ryP	MmXtV2FPT0WU
MDA-MB-157	NH64XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTN2LkixPVMh\|ryP	MoK2V2FPT0WU
LN-405	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M16zdWlEPTB;M{WuOFMxQCEQvF2=	M3\6PXNCVkeHUh?=
MDA-MB-231	NWrsb\|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTN3LkWwOVQh\|ryP	M1nhVXNCVkeHUh?=
EW-24	NIS1[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j2RmlEPTB;M{WuOlM{PSEQvF2=	NFfWRmhUSU6JRWK=
MKN28	M3;UN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHZ[\|lyUUN3ME2zOU45OjN4IN88US=>	NYT2NoJwW0GQR1XS
KINGS-1	NYPTPFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\RPGlEPTB;M{WuPFQ{PCEQvF2=	Ml7mV2FPT0WU
LC-2-ad	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHP2S5ZKSzVyPUO2MlY6QSEQvF2=	NYqyRmg2W0GQR1XS
IGR-1	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DqRWlEPTB;M{[uO\|A4PSEQvF2=	M2ewW3NCVkeHUh?=
SW626	M2PUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\NfWlEPTB;M{euNFQyPyEQvF2=	MYnTRW5ITVJ?
ONS-76	NX7reJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXOTWM2OD1\|Nz6xN\|A6KM7:TR?=	M4jwcnNCVkeHUh?=
T98G	M33SPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\5XmlEPTB;M{euPFY{PSEQvF2=	MoLKV2FPT0WU
NB14	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3jTWM2OD1\|OD60OVQ1KM7:TR?=	NGm5fopUSU6JRWK=
D-423MG	M{\5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzHRVNVUUN3ME2zPE41QDZ7IN88US=>	MV3TRW5ITVJ?
NCI-H510A	M4izTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XCNmlEPTB;M{iuOlQ2OSEQvF2=	MXHTRW5ITVJ?
NMC-G1	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XDOWlEPTB;M{iuO\|IzOiEQvF2=	NEHoWJNUSU6JRWK=
SW948	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;GPFRuUUN3ME2zPE45QTR7IN88US=>	NWTKTGpVW0GQR1XS
MFM-223	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfxe\|hJUUN3ME2zPE46PDNzIN88US=>	NVG4OGhLW0GQR1XS
PAN1	NEi1c4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTN6Lkm5NVkh\|ryP	M4KzbHNCVkeHUh?=
MZ7-mel	NUPP[4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXBZWhKSzVyPUO5MlEyQTlizszN	NYHlSI1TW0GQR1XS
COLO-679	NXTTTW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HMV2lEPTB;M{muPVcxQCEQvF2=	M1Xib3NCVkeHUh?=
SW872	NHLBfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTRyLkKwN\|Eh\|ryP	M2mxe3NCVkeHUh?=
HT-1197	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3nTlJKSzVyPUSwMlI5PjlizszN	M2LNeHNCVkeHUh?=
ES6	M2DZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fQbGlEPTB;NECuOFU2OiEQvF2=	Mme2V2FPT0WU
SNU-387	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH20ZmpKSzVyPUSwMlgzOzhizszN	NYf5eGloW0GQR1XS
T47D	NEHLW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXkVFZKSzVyPUSxMlAyQTJizszN	NXfSRXgxW0GQR1XS
G-402	NUO0dWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHmzbGpKSzVyPUSxMlA5ODlizszN	NGrkdYlUSU6JRWK=
MZ1-PC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEWwNHVKSzVyPUSxMlgyKM7:TR?=	MX3TRW5ITVJ?
SW1417	NFXnZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnZTWM2OD12Mj6zNFMh\|ryP	MVLTRW5ITVJ?
RERF-LC-MS	NGjqUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS0TWM2OD12Mj61NFg4KM7:TR?=	NGPoXnpUSU6JRWK=
SF539	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PYR2lEPTB;NEKuOVUzQSEQvF2=	MWLTRW5ITVJ?
ESS-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XWRWlEPTB;NEOuOVU2QCEQvF2=	NH;qZ3NUSU6JRWK=
RO82-W-1	NYPxR5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTR\|Lk[xOVMh\|ryP	MV\TRW5ITVJ?
S-117	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITpdIpKSzVyPUSzMlY6PThizszN	NFP6XHhUSU6JRWK=
SW756	NVLtOo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfBTWM2OD12Mz64NlQzKM7:TR?=	MWXTRW5ITVJ?
CP66-MEL	NE\WTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LWXWlEPTB;NEWuO\|E1OyEQvF2=	NF24fm1USU6JRWK=
H-EMC-SS	NH7wR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGG3[5RKSzVyPUS1Mlc3QTNizszN	M3TnUHNCVkeHUh?=
NCI-H2052	NWTUO3RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTOU5dxUUN3ME20OU46ODJ5IN88US=>	NWXn[5RbW0GQR1XS
SW684	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDITWM2OD12Nz6wNFgyKM7:TR?=	NWDHblIxW0GQR1XS
HCC1569	NUToW29mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHWd\|RSUUN3ME20O{4yPjV6IN88US=>	NXv1WmV4W0GQR1XS
KGN	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3ocIR{UUN3ME20O{4{OzFzIN88US=>	MkjCV2FPT0WU
LCLC-103H	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XSdmlEPTB;NEeuOFQxPCEQvF2=	NXf1fmQ6W0GQR1XS
SW780	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTR5Lk[zOVEh\|ryP	M2X4bnNCVkeHUh?=
NCI-H1703	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7D[pdKSzVyPUS4MlM{PTJizszN	NHXHWVRUSU6JRWK=
HCC1395	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHX6PINKSzVyPUS4Mlc1OzJizszN	NV7xSIY2W0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究

Gefitinib 作用于无胸腺裸鼠，抑制SKOV3 或MDA-MB-231 肿瘤生长。Gefitinib高效作用于两种类型肿瘤。处理14天后，MDA-MB-231肿瘤和SKOV3肿瘤生长抑制分别为71%和32%。

细胞实验：^[1]	+ 展开 Cell lines: NR6, NR6M 和 NR6W 细胞 Concentrations: 0 μM -2 μM Incubation Time: 72 小时 Method: 呈指数生长的细胞，包括 NR6, NR6M, NR6M和NR6W细胞按6倍接种在96孔板上，每孔为2000个细胞, 粘附，随后在PBS 中清洗，然后在含0.5% FCS的培养基上温育过夜。使用不同浓度(0-2 μM) Gefitinib或溶质对照DMSO 和EGF 处理细胞。诱导NR6wtEGFR和NR6W 细胞增殖的EGF最佳浓度已经测定，因此NR6wtEGFR和 NR6W 细胞中分别加入10 nM和 0.1 nM EGF。NR6 和NR6M细胞中不加入EGF。72 小时后，通过MTT 增殖检测测量细胞数。 (Only for Reference)
动物实验：^[3]	+ 展开 Animal Models: 携带 SKOV3或MDA-MB-231肿瘤的无胸腺裸鼠 Formulation: 0.2% DMSO Dosages: 75 mg/kg Administration: 饲喂处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Gefitinib (ZD1839) SDF

分子量	446.90
化学式	C₂₂H₂₄ClFN₄O₃
CAS号	184475-35-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
回答：
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

泛EGFR抑制剂

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
活性最高的EGFR抑制剂

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA批准的EGFR抑制剂

Lapatinib : Approved by FDA for breast cancer.
最新的EGFR抑制剂

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

研究领域

产品类型

Gefitinib (ZD1839)

客户使用Selleck该产品发表文献95篇：

客户使用该产品的14个实验数据：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Gefitinib (ZD1839) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

相关EGFR产品